Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival

Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in improving the survival of patients with untreated, advanced triple negative breast cancer (TNBC) using the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). Published in the Annals of Oncology, the findings demonstrate the potentia…